Drugs / B/F/TAF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02607956 | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B/F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02607956 ↗ |
| Known as | bictegravir/emtricitabine/tenofovir alafenamide | “bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment.” PMID 37200995 ↗ May 2023 |
| Route | Oral | “50/200/25 milligrams (mg) FDC tablets administered orally, once daily” NCT02607956 ↗ |